Related Experiment Video
Updated: Jun 23, 2025
A Rapid Filter Insert-based 3D Culture System for Primary Prostate Cell Differentiation
Published on: February 13, 2017
Patient-Derived Conditionally Reprogrammed Cells in Prostate Cancer Research
Abdalla Elbialy1,2, Deepthi Kappala1, Dhruv Desai1
1OSU Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA.
Abstract:
Prostate cancer (PCa) remains a leading cause of mortality among American men, with metastatic and recurrent disease posing significant therapeutic challenges due to a limited comprehension of the underlying biological processes governing disease initiation, dormancy, and progression. The conventional use of PCa cell lines has proven inadequate in elucidating the intricate molecular mechanisms driving PCa carcinogenesis, hindering the development of effective treatments. To address this gap, patient-derived primary cell cultures have been developed and play a pivotal role in unraveling the pathophysiological intricacies unique to PCa in each individual, offering valuable insights for translational research. This review explores the applications of the conditional reprogramming (CR) cell culture approach, showcasing its capability to rapidly and effectively cultivate patient-derived normal and tumor cells. The CR strategy facilitates the acquisition of stem cell properties by primary cells, precisely recapitulating the human pathophysiology of PCa. This nuanced understanding enables the identification of novel therapeutics. Specifically, our discussion encompasses the utility of CR cells in elucidating PCa initiation and progression, unraveling the molecular pathogenesis of metastatic PCa, addressing health disparities, and advancing personalized medicine. Coupled with the tumor organoid approach and patient-derived xenografts (PDXs), CR cells present a promising avenue for comprehending cancer biology, exploring new treatment modalities, and advancing precision medicine in the context of PCa. These approaches have been used for two NCI initiatives (PDMR: patient-derived model repositories; HCMI: human cancer models initiatives).
Insights
Conditional reprogramming (CR) cultivates patient-derived prostate cancer (PCa) cells, mimicking disease pathophysiology. This approach aids in understanding PCa initiation, progression, and developing targeted therapies.
Area of Science:
- Oncology
- Cell Biology
- Translational Research
Background:
- Prostate cancer (PCa) is a leading cause of cancer mortality in men, with metastatic and recurrent forms presenting significant therapeutic challenges.
- Conventional PCa cell lines inadequately represent the complex molecular mechanisms of carcinogenesis, limiting therapeutic development.
- Patient-derived primary cell cultures are crucial for understanding individual PCa pathophysiology and advancing translational research.
Purpose of the Study:
- To review the applications of the conditional reprogramming (CR) cell culture technique for cultivating patient-derived normal and tumor cells.
- To highlight how CR recapitulates prostate cancer pathophysiology and aids in identifying novel therapeutics.
- To discuss the utility of CR cells in understanding PCa initiation, progression, metastasis, and advancing personalized medicine.
Main Methods:
- Conditional reprogramming (CR) strategy to rapidly cultivate patient-derived normal and tumor cells.
- CR facilitates the acquisition of stem cell properties in primary cells, mirroring human PCa pathophysiology.
- Integration of CR cells with tumor organoids and patient-derived xenografts (PDXs) for comprehensive cancer modeling.
Main Results:
- CR enables effective cultivation of patient-derived prostate cancer cells, preserving their unique pathophysiological characteristics.
- The CR approach aids in elucidating the molecular pathogenesis of PCa, including initiation, progression, and metastasis.
- CR models, alongside organoids and PDXs, are instrumental in NCI initiatives like PDMR and HCMI.
Conclusions:
- Conditional reprogramming is a powerful tool for generating patient-derived prostate cancer models that accurately reflect human disease.
- CR facilitates a deeper understanding of PCa biology, enabling the discovery of new treatment strategies and personalized medicine approaches.
- The combination of CR, organoids, and PDXs offers a robust platform for advancing precision oncology in prostate cancer research.
